Driving Health for All: Reckitt Receives Global Health Awards 2025 at House of Commons, London
Business Wire India
Reckitt, a leading global consumer health and hygiene company, has been recognized with two significant accolades at the prestigious Global Health Awards 2025, held at the iconic House of Commons, UK Parliament, London, for its outstanding contribution to global healthcare. The awards were presented by The Lord Loomba, CBE, a distinguished member of the House of Lords .
At this esteemed gathering of leading voices and changemakers from the global health community, Reckitt was honoured in two key categories: Public Health Champion Award – for the flagship Dettol Banega Swasth India campaign, India's longest-running private sector-led public health movement.
Community Impact Award – for transformative work under the campaign: Self-care for New Moms and Kids Under Five.
These accolades spotlight Reckitt's purpose-led approach to healthcare – advancing hygiene, sanitation, maternal and child health, and empowering communities through awareness, education and access to drive behaviour change.
Ravi Bhatnagar, Communications and Corporate Affairs Director, South Asia, MENARP and Africa, Reckitt , said, ' At Reckitt, we believe access to highest quality of health and hygiene is a right, not a privilege — and our purpose knows no borders. We are truly honored to receive this recognition at the Global Health Awards 2025, held at the Palace of Westminster, House of Commons, London. It is a powerful reminder of the impact we can create when purpose translates into action. These awards are not just milestones, it affirms our belief that hygiene is the foundation of good health, and that collective action can drive lasting change.'
As part of its flagship campaign, Dettol Banega Swasth India, Reckitt has been leading the cause of advancing public health and hygiene in India for over a decade. Launched in 2014, it is India's longest-running private sector-led public health campaign. Rooted in the ethos of the Swachh Bharat Abhiyan, the initiative has grown into a comprehensive movement driving behavior change through sanitation, hygiene education, health awareness, and preventive care . The campaign has reached millions, championing the belief that hygiene is the foundation for good health.
Reckitt's Self-care for New Moms and Kids Under Five initiative has been focused on strengthening maternal and child health through early education, self-care literacy, and community-level support systems. With a focus on building awareness and agency among mothers, caregivers, and frontline workers, the programme empowers families to make informed, preventive health decisions—addressing crucial gaps in early childhood care and maternal wellbeing.
The Global Health Awards, organised by WBR Corp, are among the most prestigious honours in international healthcare. They celebrate the contributions of doctors, innovators, and healthcare organisations for their excellence, innovation, and commitment to improving lives worldwide.
Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same.
Ahmedabad Plane Crash
Business Wire India, established in 2002, India's premier media distribution company ensures guaranteed media coverage through its network of 30+ cities and top news agencies.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
3 hours ago
- The Hill
Something both sides agree on: A bill to prevent late-stage cancer
One million Medicare beneficiaries will be diagnosed with cancer this year. 600,000 people in the U.S. will die of cancer this year. Cancer is a leading cause of death worldwide, affecting millions of families each year. Evidence consistently shows that early detection significantly improves treatment outcomes, reduces costs and saves lives. Investing in early detection is a critical and cost-effective public health strategy. Despite this, our healthcare system is still struggling to keep up. Many Americans, especially those living on fixed incomes, in rural communities or facing already limited access to healthcare, are being diagnosed at later stages of cancer, when outcomes are poorer and treatment much more expensive. And for too many, the diagnosis arrives not just as a health crisis, but as a financial one. I have worked with too many families who find themselves facing impossible choices — buy groceries for the week or cover their cancer treatments. Against this backdrop, Congress has a rare and urgent opportunity to act. Last year, members of the House Committee on Ways and Means shared deeply personal stories of how cancer has touched their lives as they reviewed and unanimously supported the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act. So, it should come as no surprise that the act is the first and only health care bill to garner majority support in both the House and Senate. That level of bipartisan consensus is almost unheard of. But the job isn't finished until this bill becomes law. My organization, the Cancer Support Community, and other nonprofits have seen where the system fails patients. Rural communities, in particular, face significant disparities in access to timely screening and care. Our data shows that longer travel times to treatment often result in later-stage diagnoses and lower quality of life. Catching cancer early can prevent this, offering patients the opportunity to receive less aggressive (and less expensive) treatment, and most importantly, more time with loved ones. Yet many cancers still lack reliable screening tools. Expanding investment in early detection is not only a medical imperative, it's an economic one. The earlier cancer is found, the less it costs to treat and the better the chances of survival. One estimate suggests that the preventative cancer screenings we do have saved the U.S. a cumulative $6.5 trillion over the last 25 years. The Nancy Gardner Sewell Act would modernize Medicare to allow for coverage of cutting-edge screening technologies that can detect dozens of cancers through a simple blood test. This policy would mark a turning point in the fight against cancer, particularly for older adults who face the highest risk and are often diagnosed in later stages. The support is overwhelming. More than 550 organizations representing cancer patients, providers, researchers and advocates have urged lawmakers to seize this moment. Congress has already thoroughly vetted this bill and cleared it for passage. When lawmakers return from their summer break, there will be no better time to get this bill over the finish line. Everything is ready to go. The support is there. Now is the time for passage.
Engadget
6 hours ago
- Engadget
Illinois is the first state to ban AI therapists
Illinois Governor JB Pritzker has signed a bill into law banning AI therapy in the state. This makes Illinois the first state to regulate the use of AI in mental health services. The law highlights that only licensed professionals are allowed to offer counseling services in the state and forbids AI chatbots or tools from acting as a stand-alone therapist. HB 1806, titled the Wellness and Oversight for Psychological Resources Act, also specifies that licensed therapists cannot use AI to make 'therapeutic decisions' or perform any 'therapeutic communication.' It also places constraints on how mental health professionals may use AI in their work, such as specifying that its use for 'supplementary support,' such as managing appointments, billing or other administrative work, is allowed. In a statement to Mashable , Illinois State Representative Bob Morgan said, 'We have already heard the horror stories when artificial intelligence pretends to be a licensed therapist. Individuals in crisis unknowingly turned to AI for help and were pushed toward dangerous, even lethal, behaviors.' The law enshrines steep penalties in an effort to curb such outcomes, with companies or individuals facing $10,000 in fines per violation. 'This legislation stands as our commitment to safeguarding the well-being of our residents by ensuring that mental health services are delivered by trained experts who prioritize patient care above all else,' said Mario Treto Jr., secretary of the Illinois Department of Financial and Professional Regulation. The bill passed the Illinois House and Senate unanimously in a sign of overwhelming bipartisan support. The legislation is particularly notable as the Trump administration's recently-revealed AI plan outlines a 10-year moratorium on any state-level AI regulation. It also comes as OpenAI has said it is improving the ability for its models to detect mental or emotional distress and will ask users to take a break during unusually long chats.
Business Upturn
10 hours ago
- Business Upturn
Polpharma Biologics and Fresenius Kabi Sign Licensing Agreement for Proposed Vedolizumab Biosimilar PB016
Business Wire India Polpharma Biologics S.A. ('Polpharma Biologics') announces a global (except for Middle East & North Africa) licensing agreement with Fresenius Kabi for the commercialization of PB016, a proposed biosimilar to vedolizumab, an integrin receptor antagonist, (reference product: Entyvio®*), a biologic therapy indicated for moderate to severe ulcerative colitis and Crohn's disease. Under the terms of the agreement, Polpharma Biologics will lead development and manufacturing of PB016, while Fresenius Kabi will hold exclusive commercialization rights worldwide, excluding Middle East & North Africa. 'This partnership reinforces our mission to broaden access to high-quality biologics that improve patient outcomes globally,' said Konstantin Matentzoglu, Supervisory Board Member of Polpharma Biologics Group. 'Fresenius Kabi's deep commercialization experience and commitment to biosimilars make them an ideal partner for bringing PB016 to patients worldwide. Together, we are taking an important step toward addressing the rising burden of chronic inflammatory diseases.' The agreement builds on Polpharma Biologics' growing biosimilar portfolio and proven development capabilities. The company has previously brought forward multiple biosimilars — including ranibizumab and natalizumab — across global markets in partnership with leading pharmaceutical companies. This strategic collaboration strengthens both companies' commitments to expanding global access to affordable biologic medicines while supporting healthcare system sustainability. *Entyvio® is a registered trademark of Takeda. About Polpharma Biologics: Polpharma Biologics is an international biotechnology company with integrated operations in the European Union (EU), developing and manufacturing biosimilar medicines. Using patented solutions and state-of-the-art platform technologies, Polpharma Biologics develops biosimilar products to treat a range of conditions in major therapeutic areas. Programs at Polpharma Biologics start in cell line development and transition through technical and clinical development to commercial-scale production preparing drugs for future commercial partnerships with global pharmaceutical organizations. The expertise of Polpharma Biologics lies in the development and manufacture of medicines based on microbial and mammalian expression systems. With its cell line development center in the Netherlands and two centers of development and manufacturing in Poland, Polpharma Biologics creates growth and development opportunities for biotechnology specialists. Learn more at About Fresenius Kabi: As part of the global healthcare company Fresenius, Fresenius Kabi specializes in (bio)pharmaceuticals, medical technologies and nutrition products for critical and chronic conditions. The company's products, technologies, and services are used for the therapy and care of critically and chronically ill patients. With more than 41,000 employees and present in over 100 countries, Fresenius Kabi's expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies. For more information, please visit Important Note This press release is for informational purposes only and does not constitute promotional material for PB016 in Poland or any other jurisdiction. The commercialization of proposed vedolizumab biosimilar PB016 is solely the responsibility of Fresenius Kabi, the marketing authorization holder, in accordance with all applicable laws and regulations. Disclaimer This press release is issued from Polpharma Biologics Group and is intended to provide worldwide information to healthcare professionals, media and (potential) investors about our global business in relation to drug development and manufacturing expertise. Although Polpharma Biologics Group is not a public company as of this date, recipients should understand that this press release contains certain forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). These statements involve inherent risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the approval and commercialization of the medicinal product, market reception, competition, changes in economic conditions and applicable laws, global regulatory developments, contractual risks and dependencies from third parties. Polpharma Biologics undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release. Moreover, Polpharma Biologics wishes to emphasize that this press release is for informational purposes only and shall not be construed as making any representation, warranties, or guarantees, either express or implied, regarding the potential approval, market reception, commercialization, or success of the medicinal product or any other product or therapy. Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same. Ahmedabad Plane Crash
